Carolyn Delucia, MD
Obstetrics & Gynecology · Hillsborough, NJNPI 1346288685
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,494 of the $1,709 with a category attached, or 87.4%. 17 manufacturers reported payments, led by AbbVie at 28.1% of the total. Reporting peaked in 2023 at $534 and has fallen 76.9% since, to $123 in 2025.
Across 109 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$480
- Astellas Pharma US Inc$213
- Mayne Pharma Commercial LLC$163
- Avion Pharmaceuticals$144
- Evofem Biosciences, Inc.$108
- Millicent US Inc$90
- plus $510 from 11 others
What the payments were for
- Food & beverage$1,49487%
- Education$21513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $480 |
| Astellas Pharma US Inc | 5 | $213 |
| Mayne Pharma Commercial LLC | 15 | $163 |
| Avion Pharmaceuticals | 11 | $144 |
| Evofem Biosciences, Inc. | 8 | $108 |
| Millicent US Inc | 5 | $90 |
| Arteriocyte Medical Systems, Inc. | 4 | $88 |
| Therapeuticsmd, Inc. | 6 | $81 |
| Revance Therapeutics, Inc. | 4 | $66 |
| Myovant Sciences Inc. | 4 | $55 |
| Scynexis, Inc. | 3 | $47 |
| Ascend Therapeutics US, LLC | 3 | $46 |
| Pfizer | 3 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| Exeltis, USA Inc. | 2 | $26 |
| Acella Pharmaceuticals, LLC | 1 | $20 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,709 in reported general payments places this provider in the 70th percentile of 1,242 obstetrics & gynecology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 75 | $6,026 |
| ProgesteroneProgesterone, Micronized | 14 | $1,024 |
| ValacyclovirValacyclovir Hcl | 21 | $839 |
| Terconazole | 31 | $718 |
| Clobetasol Propionate | 14 | $436 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $199 |
| CiclopiroxCiclopirox Olamine | 11 | $120 |
| Fluconazole | 13 | $46 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Hillsborough
- Jennifer AshtonEnglewood$1.5M
- Geoffrey BowersVoorhees$228K
- Neha DeshpandePlainsboro$206K
- Paula JasionowskiVoorhees$193K
- Justin ChuraSwedesboro$179K
- Andrea VentolaFlorham Park$145K
- Aiman ShiladPaterson$100K
- Patrick CulliganMorristown$93K
- Dipak DelvadiaCherry Hill$86K
- Susan PitmanWest Orange$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.